Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|ER Positive Breast Cancer
Interventions: DRUG: Letrozole 2.5mg
Sponsor: Dartmouth-Hitchcock Medical Center